<DOC>
	<DOCNO>NCT00599326</DOCNO>
	<brief_summary>To determine efficacy tolerability deferasirox treatment Porphyria Cutanea Tarda . Primary objective - elimination blistering within 6 month treatment . Secondary objective - decrease total body iron level .</brief_summary>
	<brief_title>Pilot Trial Deferasirox Treatment Porphyria Cutanea Tarda</brief_title>
	<detailed_description>Phlebotomy standard therapy Porphyria Cutanea Tarda ( PCT ) , inconvenient cause anemia patient . Deferasirox new class tridentate iron chelators high affinity selectivity iron . The medication administer orally , effective PCT would make convenient possibly tolerable option patient .</detailed_description>
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Erythropoietic</mesh_term>
	<mesh_term>Porphyria Cutanea Tarda</mesh_term>
	<mesh_term>Porphyrias , Hepatic</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>diagnosis Porphyria Cutanea Tarda base clinical exam 24hour urine porphyrin level Porphyria Cutanea Tarda least 3 month prior enrollment active blistering ( 3 blister erosion per month ) woman childbearing potential must use effective method contraception study , however include hormonal contraception ( oral contraceptive , hormone patch , DepoProvera injection , NUVA Ring , etc . ) treatment naive patient patient unresponsive intolerant phlebotomy Ferritin level great equal 25ng/mL patient serum creatinine upper limit normal patient receive phlebotomy control therapy pregnant breast feeding female patient liver transaminases 5 time upper limit normal patient history hypersensitivity deferasirox patient history preexist renal condition , receive medication depress renal function patient chelators history noncompliance medical regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Exjade PCT Study</keyword>
	<keyword>PCT Study</keyword>
	<keyword>Porphyria Cutanea Tarda</keyword>
</DOC>